Sign inJoin waitlistJoin the waitlist

Mike Cusnir

Co-Director, Gastrointestinal Malignancies · Mount Sinai Medical Center of Florida, Inc

Credentials: · · · · ·

History

Gastrointestinal Malignancies · Mount Sinai Medical Center of Florida, Inc
Present
Braman Comprehensive Cancer Center Division · Mount Sinai Medical Center of Florida, Inc
Present
Mount Sinai Medical Center of Florida, Inc
Present

Hematology and Medical Oncology
UNIVERSITY OF MARYLAND MEDICAL SYSTEM CORPORATION
2000–2003
Mount Sinai Health System
1997–2000
Maimonides Medical Center
1994–1997
PONTIFICIA UNIV, FAC DE MED, JAVERIANA, BOGOTA, COLOMBIA
1990–1994

Research

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint…
Journal for ImmunoTherapy of Cancer · 2022 · 311 citations
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Clinical Cancer Research · 2019 · 203 citations
Management of Locally Advanced Rectal Cancer: ASCO Guideline
Systematic review or meta-analysis · Journal of Clinical Oncology · 2024 · 150 citations

Michael Schwartz
8 papers
VS
Vathany Sriganeshan
6 papers
Kritika Krishnamurthy
5 papers · 5 as a fellow
Robert Poppiti
5 papers
Michael Francavilla
3 papers · 3 as a resident
SA
Sarah Alghamdi
3 papers · 1 as a fellow
SZ
Simon Zeichner
3 papers · 3 as a resident
Aaron Scott
2 papers · 1 as a fellow
AB
Afsaneh Barzi
2 papers
AH
Alicia Hirzel
2 papers · 2 as a resident
AS
Amod Sarnaik
2 papers
Arnold Blaustein
2 papers

Clinical trials

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Site PI · Recruiting · Phase 3
InnoPharmax Inc.
2026–2028
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2027
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028